Great question, Gary. Yes, NWBO absolutely has input during the labeling phase.
This is not a passive observation period for the company. It is an active, structured negotiation between the sponsor and the regulator. The labeling phase centers around the Summary of Product Characteristics, which defines exactly how the therapy will be used in clinical practice. That includes the indication, patient population, method of administration, dosing, safety profile, and references to efficacy data.
NWBO initiates this phase by submitting a proposed label based on the clinical trial results. From there, the regulator reviews and responds with formal requests for clarification or modification. The company must address each point directly and provide supporting evidence. In some cases, the regulator may push for narrower language. In others, they may ask the sponsor to expand or clarify claims for safety, special populations, or follow-up procedures.
This back and forth can take multiple rounds. Each revision must be agreed upon before the regulator can finalize the approved label. The company is deeply involved in shaping every section because the label becomes the legal and medical foundation for how the product can be prescribed, reimbursed, and promoted.
So to answer your question directly, this is not regulators reaching an agreement with one another. NWBO is a central participant in the process from start to finish.
And if I had to guess, this is probably exactly what they are doing right now. It’s the final piece of the process, and it’s a step that takes precision. My birthday is coming up in mid-August, so naturally I’m hoping we’ll see approval before then. But either way, I’m not worried. We’re close, and I’m prepared to wait however long it takes. At this point, the rest is about timing.
Bullish
Market Data 
Markets 
AI
